Journal of Infectious Diseases & Therapy
Open Access

Research Article

The Use of Chemokines and Soluble TNF-α Receptors to Evaluate Patients Treated for Paracoccidioidomycosis

Lílian da Silva Santos1,3*, Weverton César Siqueira2, Samuel Gonçalves da Cruz2, Camila Cristiane Silva Camelo2, Valdirene Silva Siqueira2, Carolina Venâncio Barbosa2, Alexandre Alvim Ambrósio2, Ana Carla de Carvalho Dantônio2, Alfredo Miranda de Goes3 and Ênio Pietra Pedroso1,2
1Programa de Pós-graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil
2Faculdade de Medicina, UFMG, Belo Horizonte, Minas Gerais, Brazil
3Laboratório de Imunologia Celular e Molecular, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, UFMG, Belo Horizonte, Minas Gerais, Brazil
Corresponding Author :	Lílian da Silva Santos Service de Médecine Tropicale et Humanitaire Avenue de Beau-Séjour, 22, Genève – 1206 Université de Genève, Geneva, Switzerland Tel: +41-0-22 372 96 15 E-mail: lilianufop@yahoo.com.br
Received Octomber 10, 2014; Accepted January 03, 2015; Published January 07, 2015
Citation: Santos LS, Siqueira WC, da Cruz SG, Silva Camelo CC, Siqueira VS, et al. (2015) The Use of Chemokines and Soluble TNF-α Receptors to Evaluate Patients Treated for Paracoccidioidomycosis. J Infect Dis Ther 3:201. doi: 10.4172/2332-0877.1000201
Copyright: © 2014 Santos LS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed Scholar Google

Paracoccidioidomycosis (PCM) is a systemic disease with high prevalence in Brazil and some countries in Latin America. This study aimed to evaluate patients treated for PCM in an endemic area, to verify the use of serological markers in the control of cure of this mycosis. A follow-up study of 42 months was conducted with 26 patients, which had blood samples collected during and after treatment. All measures of serological markers were made by ELISA. The dosage of IgG, sTNF-RI and sTNF-RII allowed the segregation of majority of patients with PCM from health individuals during almost all the period analyzed. Although, some patients did not present detected levels of IgG and sTNF-RI at any moment. Concentrations of CCL2 and CCL3 were high during the treatment, with a tendency of decreasing along the time. CCL11 was detected with concentrations below the cut-off point during treatment, with increasing from the moment of its interruption. Concentrations of CCL24 did not change along the period analyzed. CXCL9 presented low concentrations during and after the interruption of treatment, without any association with clinical aspects. The variable concentrations found for all serological markers tested show the insecurity to use this parameters and the need of a continuous search for new markers to evaluate the control of cure of patients treated for PCM.

Keywords